ReviewJournal of the American Society of Nephrology : JASN2026
Hypertension Management in Pregnancy and Postpartum.
Review in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive disorders of pregnancy affect approximately 9% of pregnancies in the United States and are a leading cause of maternal morbidity and mortality. For nephrologists, these conditions sit at a critical intersection: CKD is among the strongest risk factors of preeclampsia, and pregnancy itself can unmask previously unrecognized kidney disease. The physiologic demands of gestation stress renal and vascular reserve in ways that make the pregnant and immediately postpartum patient particularly vulnerable. Preeclampsia, driven by placental release of antiangiogenic factors and widespread maternal endothelial dysfunction, produces acute cardiorenal injury that does not entirely resolve with delivery. Postpartum hypertension peaks between days 3 and 6 after delivery and is under-recognized, yet this period carries the greatest risk of preventable maternal death, with cardiovascular causes accounting for more than one third of pregnancy-related deaths. Beyond the acute phase, women with hypertensive pregnancies face accelerated trajectories toward chronic hypertension, CKD, and overall cardiometabolic risks that compound with each affected pregnancy. The postpartum visit represents a critical and underutilized opportunity to identify women who warrant nephrology evaluation, initiate renoprotective therapy, and interrupt a long-term cardiorenal disease course. Nephrologists are well positioned to recognize cardiorenal sequelae of hypertensive pregnancy and ensure that the postpartum period is not a missed opportunity for intervention. This review addresses the diagnosis, pathophysiology, and management of hypertensive disorders across the full peripartum continuum, with particular attention to the role of nephrologists in recognizing kidney disease that pregnancy has brought to light and in ensuring that delivery is not treated as a clinical end point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.